Saint-Prex, Switzerland, 19 February 2009. Today, Ferring Pharmaceuticals announced the creation of a new Executive Board. This reflects the substantial growth of the company over the past few years and the subsequent need to adapt the management structure. The Executive Board will be led by Michel Pettigrew, President of the Executive Board and Chief Operating Officer, and will report to the Board of Directors.
Frederik Paulsen, Chairman of Ferring Pharmaceuticals, said;
"This is a very important step in the development of Ferring. We have enjoyed considerable success over the past few years, and grown substantially. This will help us consolidate our position and push on to the next phase of our growth."
The Executive Board will have collective responsibility for all aspects of the company's operational management, including legal and ethical compliance and Ferring's Standard Operating procedures. It will also, importantly, manage adherence to the Ferring Philosophy, the values which underpin the company's activities.
Michel Pettigrew, commenting on his appointment, said:
"I am delighted to have been appointed President of the Executive Board. Ferring has expanded considerably into new geographies and markets and the Executive Board will strengthen our corporate professionalism and efficiency, and help position us for further success globally in the future."
As well as Michel Pettigrew, the Executive Board will comprise, Peter Wilden (Chief Financial Officer), Pascal Danglas (Executive Vice-President Clinical & product development), and Jean Duvall (Group General Counsel).
Ferring Pharmaceuticals is a Swiss-based research driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of endocrinology, gastroenterology, gynaecology, fertility and urology. In recent years Ferring has expanded beyond its traditional European base and has operations in over 40 countries. To learn more about Ferring or its products please visit www.ferring.com.
Tel: +41 58 301 00 51, Fax: +41 58 301 0039